Celldex Therapeutics Inc
Celldex is a clinical stage biotechnology company leading the science at the intersection of mast cell biology and the development of transformative therapeutics for patients. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Visit www.celldex.com.
Current Price
$31.34
-3.42%Celldex Therapeutics Inc (CLDX) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Celldex Therapeutics Inc's financial performance and position as a Healthcare company.
Trailing twelve-month (TTM) revenue is $866000.00. Gross profit (TTM) is $866000.00. EBITDA is $-280.28M. Earnings per share (EPS) is $-3.90. The P/E ratio is -7.35. Market capitalization is $2.09B.
Free cash flow (FCF) is $-213.66M. Weighted average cost of capital (WACC) is 10.00%.
Historical revenue data covers 7 years from FY19 to FY25. Net income history spans 7 years. Free cash flow and capital expenditure data spans 7 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.
Use Celldex Therapeutics Inc's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.
